Mesulergine (BioDeep_00000843711)

   


代谢物信息卡片


Mesulergine

化学式: C18H26N4O2S (362.1776376)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN1CC(CC2C1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C
InChI: InChI=1S/C18H26N4O2S/c1-20(2)25(23,24)19-13-9-15-14-6-5-7-16-18(14)12(10-21(16)3)8-17(15)22(4)11-13/h5-7,10,13,15,17,19H,8-9,11H2,1-4H3/t13-,15+,17+/m0/s1

描述信息

D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
A member of the class of ergot alkaloids that is known to act on serotonin and dopamine receptors.
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist

同义名列表

1 个代谢物同义名

Mesulergine



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Arvind Negi, Ciaran O Reilly, Dilip V Jarikote, Jian Zhou, Paul V Murphy. Multi-targeting protein-protein interaction inhibitors: Evolution of macrocyclic ligands with embedded carbohydrates (MECs) to improve selectivity. European journal of medicinal chemistry. 2019 Aug; 176(?):292-309. doi: 10.1016/j.ejmech.2019.04.064. [PMID: 31112891]
  • Jakob A Shimshoni, Eyal Sobol, Ezekiel Golan, Yulius Ben Ari, Orit Gal. Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2-aminoindane (MEAI): A new binge-mitigating agent. Toxicology and applied pharmacology. 2018 03; 343(?):29-39. doi: 10.1016/j.taap.2018.02.009. [PMID: 29458138]
  • Jan Anker Jahnsen, Staffan Uhlén. The N-terminal region of the human 5-HT₂C receptor has as a cleavable signal peptide. European journal of pharmacology. 2012 Jun; 684(1-3):44-50. doi: 10.1016/j.ejphar.2012.03.043. [PMID: 22497996]
  • Robert A Ettlin, Junji Kuroda, Stephanie Plassmann, Makoto Hayashi, David E Prentice. Successful drug development despite adverse preclinical findings part 2: examples. Journal of toxicologic pathology. 2010 Dec; 23(4):213-34. doi: 10.1293/tox.23.213. [PMID: 22272032]
  • Amee Krishnakumar, M S Nandhu, C S Paulose. Upregulation of 5-HT2C receptors in hippocampus of pilocarpine-induced epileptic rats: antagonism by Bacopa monnieri. Epilepsy & behavior : E&B. 2009 Oct; 16(2):225-30. doi: 10.1016/j.yebeh.2009.07.031. [PMID: 19700373]
  • Amee Krishnakumar, Pretty Mary Abraham, Jes Paul, C S Paulose. Down-regulation of cerebellar 5-HT(2C) receptors in pilocarpine-induced epilepsy in rats: therapeutic role of Bacopa monnieri extract. Journal of the neurological sciences. 2009 Sep; 284(1-2):124-8. doi: 10.1016/j.jns.2009.04.032. [PMID: 19439326]
  • Benjamin Chanrion, Clotilde Mannoury la Cour, Sophie Gavarini, Mathieu Seimandi, Laurent Vincent, Jean-François Pujol, Joël Bockaert, Philippe Marin, Mark J Millan. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Molecular pharmacology. 2008 Mar; 73(3):748-57. doi: 10.1124/mol.107.041574. [PMID: 18083778]
  • T M du Bois, C Deng, W Bell, X-F Huang. Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain. Neuroscience. 2006; 139(4):1397-403. doi: 10.1016/j.neuroscience.2006.02.068. [PMID: 16600514]
  • Michael Brüss, Sibylle Kiel, Heinz Bönisch, Arevat Kostanian, Manfred Göthert. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor. Neurochemistry international. 2005 Aug; 47(3):196-203. doi: 10.1016/j.neuint.2005.03.003. [PMID: 15896881]
  • Jeffrey Sprouse, Linda Reynolds, Xingfang Li, John Braselton, Anne Schmidt. 8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology. 2004 Jan; 46(1):52-62. doi: 10.1016/j.neuropharm.2003.08.007. [PMID: 14654097]
  • Julie Y Crider, Gary W Williams, Colene D Drace, Parvaneh Katoli, Michelle Senchyna, Najam A Sharif. Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells. Investigative ophthalmology & visual science. 2003 Nov; 44(11):4837-44. doi: 10.1167/iovs.02-1292. [PMID: 14578406]
  • Ebenezer K C Kong, Liang Peng, Ye Chen, Albert C H Yu, Leif Hertz. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochemical research. 2002 Feb; 27(1-2):113-20. doi: 10.1023/a:1014862808126. [PMID: 11930908]
  • G L Alberts, C L Chio, W B Im. Allosteric modulation of the human 5-HT(7A) receptor by lipidic amphipathic compounds. Molecular pharmacology. 2001 Dec; 60(6):1349-55. doi: 10.1124/mol.60.6.1349. [PMID: 11723242]
  • K Quirk, A Lawrence, J Jones, A Misra, V Harvey, H Lamb, D Revell, R H Porter, A R Knight. Characterisation of agonist binding on human 5-HT2C receptor isoforms. European journal of pharmacology. 2001 May; 419(2-3):107-12. doi: 10.1016/s0014-2999(01)00943-8. [PMID: 11426831]
  • G L Alberts, J F Pregenzer, W B Im, P G Zaworski, G S Gill. Agonist-induced GTPgamma35S binding mediated by human 5-HT(2C) receptors expressed in human embryonic kidney 293 cells. European journal of pharmacology. 1999 Nov; 383(3):311-9. doi: 10.1016/s0014-2999(99)00653-6. [PMID: 10594325]
  • G Campiani, E Morelli, S Gemma, V Nacci, S Butini, M Hamon, E Novellino, G Greco, A Cagnotto, M Goegan, L Cervo, F Dalla Valle, C Fracasso, S Caccia, T Mennini. Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studies. Journal of medicinal chemistry. 1999 Oct; 42(21):4362-79. doi: 10.1021/jm990151g. [PMID: 10543880]
  • G Campiani, A Cappelli, V Nacci, M Anzini, S Vomero, M Hamon, A Cagnotto, C Fracasso, C Uboldi, S Caccia, S Consolo, T Mennini. Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. Journal of medicinal chemistry. 1997 Oct; 40(22):3670-8. doi: 10.1021/jm970376w. [PMID: 9357534]
  • F G Boess, F J Monsma, V Meyer, C Zwingelstein, A J Sleight. Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor. Molecular pharmacology. 1997 Sep; 52(3):515-23. doi: 10.1124/mol.52.3.515. [PMID: 9284367]
  • M S Grotewiel, E Sanders-Bush. Regulation of serotonin2A receptors in heterologous expression systems. Journal of neurochemistry. 1994 Oct; 63(4):1255-60. doi: 10.1046/j.1471-4159.1994.63041255.x. [PMID: 7931277]
  • Y Shen, F J Monsma, M A Metcalf, P A Jose, M W Hamblin, D R Sibley. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. The Journal of biological chemistry. 1993 Aug; 268(24):18200-4. doi: . [PMID: 8394362]
  • C S Aulakh, J L Hill, D L Murphy. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats. The Journal of pharmacology and experimental therapeutics. 1992 Nov; 263(2):588-95. doi: . [PMID: 1432690]
  • H Pisarek, H Stepien, M Pawlikowski. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary. Endocrine regulations. 1992 Mar; 26(1):17-22. doi: NULL. [PMID: 1421203]
  • H Tamir, K P Liu, S C Hsiung, P Y Yu, A L Kirchgessner, M D Gershon. Identification of serotonin receptors recognized by anti-idiotypic antibodies. Journal of neurochemistry. 1991 Sep; 57(3):930-42. doi: 10.1111/j.1471-4159.1991.tb08240.x. [PMID: 1861158]
  • D Julius, K N Huang, T J Livelli, R Axel, T M Jessell. The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proceedings of the National Academy of Sciences of the United States of America. 1990 Feb; 87(3):928-32. doi: 10.1073/pnas.87.3.928. [PMID: 2300586]
  • B H King, C Brazell, C T Dourish, D N Middlemiss. MK-212 increases rat plasma ACTH concentration by activation of the 5-HT1C receptor subtype. Neuroscience letters. 1989 Oct; 105(1-2):174-6. doi: 10.1016/0304-3940(89)90032-3. [PMID: 2562060]
  • J S Hesla, E F Rodman, M E Molitch, L A Goodman, R J Chang. The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women. Fertility and sterility. 1987 Oct; 48(4):555-9. doi: NULL. [PMID: 3653414]
  • G Brabant, I Brennecke, H Herrmann, H Friedrich, T O Wagner, A von zur Mühlen, R D Hesch. [Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy]. Deutsche medizinische Wochenschrift (1946). 1985 Oct; 110(41):1564-7. doi: 10.1055/s-2008-1069047. [PMID: 4042883]
  • A Grossman, R Ross, M Charlesworth, C B Adams, J A Wass, I Doniach, G M Besser. The effect of dopamine agonist therapy on large functionless pituitary tumours. Clinical endocrinology. 1985 May; 22(5):679-86. doi: 10.1111/j.1365-2265.1985.tb03004.x. [PMID: 4028461]
  • A Grossman, P M Bouloux, R Loneragan, L H Rees, J A Wass, G M Besser. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia. Clinical endocrinology. 1985 May; 22(5):611-6. doi: 10.1111/j.1365-2265.1985.tb02996.x. [PMID: 4028459]
  • P C Eskildsen, E Hommel, J Buchhave. The effect of a new ergoline derivative, CU 32-085, in the treatment of acromegaly. A controlled study. Clinical endocrinology. 1985 Feb; 22(2):189-200. doi: 10.1111/j.1365-2265.1985.tb01080.x. [PMID: 3886207]
  • J L Borges, H F Schran, W S Evans, A D Rogol, D L Kaiser, R M MacLeod, R L Boyett, R L Elton, M O Thorner. Mesulergine, a new dopamine agonist: effects on anterior pituitary function and kinetics. Clinical pharmacology and therapeutics. 1984 Nov; 36(5):696-703. doi: 10.1038/clpt.1984.242. [PMID: 6386276]
  • A Enz, P Donatsch, R Nordmann. Dopaminergic properties of mesulergine (CU 32-085) and its metabolites. Journal of neural transmission. 1984; 60(3-4):225-38. doi: 10.1007/bf01249095. [PMID: 6527137]
  • H Kvist Poulsen, P Rasmussen, M Riber Petersen, S Møller Pedersen. Puerperal lactation inhibition with a novel 8 alpha-aminoergoline (CU 32-085). Gynecologic and obstetric investigation. 1984; 17(3):139-44. doi: 10.1159/000299137. [PMID: 6706248]
  • R Markstein. Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors. European journal of pharmacology. 1983 Nov; 95(1-2):101-7. doi: 10.1016/0014-2999(83)90272-8. [PMID: 6230246]